Setting a new standard through research
Best-in-class care depends on best-in-class assessment
Prospera is the most advanced cfDNA solution for assessing transplant rejection — reinforced by ongoing research efforts.
Sigdel et al Clinical Validation: Published in 2019
- Conducted with the University of California, San Francisco
- Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA
- The first to publish performance of cell-free DNA testing in subclinical, surveillance setting
ProActive Registry Study: Now Enrolling
- Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplants studied for three years
- Long-term assessment of high-risk recipients for up to 5 years post-transplantation
- Personalized transplant management protocols using cell-free DNA data
Visit the ProActive Study
Read about ProActive Recruitment Milestone
View study
Research with the Molecular Microscope Diagnostic System (MMDX): Now Enrolling
- Global, prospective multicenter study under the leadership of Dr. Philip Halloran
- 300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
- Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation
PEDAL Study: Now Enrolling
- 500 kidney transplant patients from 20 major US centers
- Evaluation of how quantifying the absolute concentration of background cell-free DNA (cfDNA) may allow for a more precise and confident assessment of allograft rejection — especially in identifying patients at-risk of false-negative interpretations
Natera’s Innovations in Transplant Oncology
- CONCERT Study: To accelerate clearance for renal transplantation in molecular residual disease (MRD)-negative patients with a history of colorectal cancer
- PARC Study: To understand how malignancies and cancer therapy affect background cell-free DNA levels in renal allograft patients
- SIGNAL Study: To observe Signatera in patients with liver cancer to determine molecular residual disease (MRD) rates before and after liver transplant
MOTR Study: Now Enrolling
- Study to determine utility of Prospera in multiple organ transplant patients
- Evaluate 400 kidney-liver, kidney-pancreas and kidney-heart patients